Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, 2seventy bio is raising $170,000,009.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Chip Baird played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 2seventy bio
At 2seventy bio we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. Our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action270 miles per hour, and at 2seventy, we think in the language of time. With a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, were applying this knowledge and expertise to new classes of cellular therapies that are designed to think smarter and faster than cancer. It is this mindset that propels us forward because we know that time matters every day, every minute, every second to people living with cancer.

To learn more about 2seventy bio, visit http://www.2seventybio.com/

Contact:
Chip Baird, Chief Financial Officer
339-499-9300
chip.baird@2seventybio.com
https://www.linkedin.com/in/chip-baird-231273/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved